{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Interstitial+Lung+Disease+%28ILD%29&page=7", "query": { "condition": "Interstitial Lung Disease (ILD)", "page": 7 }, "page_size": 10 }, "pagination": { "page": 7, "page_size": 10, "total_count": 596, "total_pages": 60, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Interstitial+Lung+Disease+%28ILD%29&page=8&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Interstitial+Lung+Disease+%28ILD%29&page=6&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T05:23:14.133Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00001596", "title": "Oral Pirfenidone for the Pulmonary Fibrosis of Hermansky-Pudlak Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Albinism", "Inborn Errors of Metabolism", "Oculocutaneous Albinism", "Platelet Storage Pool Deficiency", "Pulmonary Fibrosis" ], "interventions": [ { "name": "Pirfenidone", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "William Gahl, M.D.", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2005-09", "completion_date": "2016-05-09", "has_results": true, "last_update_posted_date": "2017-10-16", "last_synced_at": "2026-10-15T05:23:14.133Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001596" }, { "nct_id": "NCT03526250", "title": "Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Malignant Solid Neoplasm", "Recurrent Childhood Ependymoma", "Recurrent Ewing Sarcoma", "Recurrent Glioma", "Recurrent Hepatoblastoma", "Recurrent Kidney Wilms Tumor", "Recurrent Langerhans Cell Histiocytosis", "Recurrent Malignant Germ Cell Tumor", "Recurrent Malignant Glioma", "Recurrent Medulloblastoma", "Recurrent Neuroblastoma", "Recurrent Non-Hodgkin Lymphoma", "Recurrent Osteosarcoma", "Recurrent Peripheral Primitive Neuroectodermal Tumor", "Recurrent Rhabdoid Tumor", "Recurrent Rhabdomyosarcoma", "Recurrent Soft Tissue Sarcoma", "Refractory Ependymoma", "Refractory Ewing Sarcoma", "Refractory Glioma", "Refractory Hepatoblastoma", "Refractory Langerhans Cell Histiocytosis", "Refractory Malignant Germ Cell Tumor", "Refractory Malignant Glioma", "Refractory Medulloblastoma", "Refractory Neuroblastoma", "Refractory Non-Hodgkin Lymphoma", "Refractory Osteosarcoma", "Refractory Peripheral Primitive Neuroectodermal Tumor", "Refractory Rhabdoid Tumor", "Refractory Rhabdomyosarcoma", "Refractory Soft Tissue Sarcoma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "21 Years", "sex": "ALL", "summary": "12 Months to 21 Years" }, "enrollment_count": 23, "start_date": "2018-08-13", "completion_date": "2024-09-30", "has_results": true, "last_update_posted_date": "2026-04-03", "last_synced_at": "2026-10-15T05:23:14.133Z", "location_count": 115, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 93 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03526250" }, { "nct_id": "NCT05321420", "title": "LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Idiopathic Pulmonary Fibrosis" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Pirfenidone", "type": "DRUG" }, { "name": "Deupirfenidone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "PureTech", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 240, "start_date": "2022-07-22", "completion_date": "2025-12-31", "has_results": false, "last_update_posted_date": "2025-10-16", "last_synced_at": "2026-10-15T05:23:14.133Z", "location_count": 22, "location_summary": "Birmingham, Alabama • Los Angeles, California • Newport Beach, California + 19 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Redding", "state": "California" }, { "city": "Torrance", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05321420" }, { "nct_id": "NCT00104299", "title": "Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Vasculitis", "Wegener's Granulomatosis", "Microscopic Polyangiitis" ], "interventions": [ { "name": "Rituximab plus cyclophosphamide placebo (rituximab group)", "type": "DRUG" }, { "name": "Cyclophosphamide plus rituximab placebo (control group)", "type": "DRUG" }, { "name": "Azathioprine", "type": "DRUG" }, { "name": "Methylprednisolone (or other glucocorticoid)", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": null, "sex": "ALL", "summary": "15 Years and older" }, "enrollment_count": 197, "start_date": "2005-01", "completion_date": "2010-01", "has_results": true, "last_update_posted_date": "2017-04-21", "last_synced_at": "2026-10-15T05:23:14.133Z", "location_count": 7, "location_summary": "Birmingham, Alabama • Baltimore, Maryland • Boston, Massachusetts + 4 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00104299" }, { "nct_id": "NCT07613099", "title": "Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) PET/CT Imaging", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Allogeneic Stem Cell Transplantation", "Lung Allograft Transplantation", "Interstitial Lung Disease", "Acute Lung Injury", "Pulmonary Arterial Hypertension", "Cardiovascular Diseases" ], "interventions": [ { "name": "[18F]FAPI-74", "type": "DRUG" }, { "name": "18F-FAPI-74 PET/CT Imaging", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST" ], "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 210, "start_date": "2026-09-18", "completion_date": "2033-05-26", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-10-15T05:23:14.133Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT07613099" }, { "nct_id": "NCT00176826", "title": "T-Cell Depletion and Stem Cell Transplant for Immune Deficiencies and Histiocytic Disorders", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Hemophagocytic Lymphohistiocytosis", "X-Linked Lymphoproliferative Disorders", "Chediak-Higashi Syndrome", "Griscelli Syndrome", "Immunologic Diseases", "Langerhans-Cell Histiocytosis", "Hematologic Diseases" ], "interventions": [ { "name": "Stem Cell Transplant", "type": "PROCEDURE" }, { "name": "Myeloablative conditioning regimen", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "55 Years", "sex": "ALL", "summary": "Up to 55 Years" }, "enrollment_count": 22, "start_date": "2000-09", "completion_date": "2015-08", "has_results": true, "last_update_posted_date": "2018-01-23", "last_synced_at": "2026-10-15T05:23:14.133Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00176826" }, { "nct_id": "NCT01262001", "title": "Safety, Tolerability, and Efficacy Study of Idiopathic Pulmonary Fibrosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Idiopathic Pulmonary Fibrosis" ], "interventions": [ { "name": "FG-3019", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kyntra Bio", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "35 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "35 Years to 80 Years" }, "enrollment_count": 90, "start_date": "2011-03", "completion_date": "2017-06-21", "has_results": false, "last_update_posted_date": "2019-10-09", "last_synced_at": "2026-10-15T05:23:14.133Z", "location_count": 18, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • New Haven, Connecticut + 15 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Orlando", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01262001" }, { "nct_id": "NCT00692796", "title": "Pulmonary Rehabilitation for Idiopathic Pulmonary Fibrosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Idiopathic Pulmonary Fibrosis" ], "interventions": [ { "name": "Pulmonary rehabilitation", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "National Jewish Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "40 Years to 90 Years" }, "enrollment_count": 60, "start_date": "2008-04", "completion_date": "2010-03", "has_results": false, "last_update_posted_date": "2017-03-29", "last_synced_at": "2026-10-15T05:23:14.133Z", "location_count": 1, "location_summary": "Denver, Colorado", "locations": [ { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00692796" }, { "nct_id": "NCT02055222", "title": "Clinical Outcomes and Molecular Phenotypes in Smokers With Parenchymal Lung Disease", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Pulmonary Fibrosis", "Lung Disease" ], "interventions": [], "intervention_types": [], "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "40 Years to 80 Years" }, "enrollment_count": 7, "start_date": "2014-10-14", "completion_date": "2018-08-23", "has_results": false, "last_update_posted_date": "2022-06-01", "last_synced_at": "2026-10-15T05:23:14.133Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02055222" }, { "nct_id": "NCT02315586", "title": "Characterization of Apolipoprotein A-I Pathways in Idiopathic Pulmonary Fibrosis", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Idiopathic Pulmonary Fibrosis" ], "interventions": [], "intervention_types": [], "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 63, "start_date": "2015-01-28", "completion_date": "2022-02-23", "has_results": false, "last_update_posted_date": "2024-09-19", "last_synced_at": "2026-10-15T05:23:14.133Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02315586" } ] }